ClinicalTrials.gg
RecruitingNCT06711731SEALUpdated Dec 2, 2024

The Freiburg Registry on SpontanEous IntercrAnial Hypotension (SIH) & Post-duraL Puncture Headache (PDPH)

An observational study in CerebroSpinal Fluid (CSF) Leak, sponsored by University Hospital Freiburg. Recruiting at 1 site in Germany. Per ClinicalTrials.gov, last updated 2024-12-02.

Sponsored by University Hospital Freiburg · Observational

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Sex
All
01

Study summary

Spinal CSF leaks are considered as rare disease. They cause a variety of symptoms, mainly culminating in a chronic headache syndrome. Crucially, yet often disregarded, the disease holds the potential for cure. The multitude of symptoms, and their inconsistency over time are just two of many challenges preventing timely diagnosis and treatment in many patients.

Spinal CSF leaks can occur after intentional or accidental dural puncture (post-dural puncture headache - PDPH) or spontaneously (spontaneous intracranial hypotension - SIH). Awareness is steadily increasing with simultaneous increase of recognized patients. Yet, research and diagnostic is mainly provided by few specialized centers, as e.g. Freiburg. Thus, many observations point towards a large non-diagnosed and non-recognized number of patients, most likely being misdiagnosed and mistreated.

Objective: The aim of the registry is to collect structured information on the frequency, cause, symptoms, diagnostic procedures, treatment options and long-term outcome. With the help of the registry, we would like to contribute to a better understanding and treatment of the diseases.

Methods: Prospective, longitudinal registry on patients with suspected SIH or PDPH, including data on demographics, clinical presentation, diagnostic findings, treatment, at treatment outcome.

Read the detailed description

Spinal CSF leaks have a severe impact on quality of life and health. Symptoms vary from chronic headache syndrome to intracranial bleeding, cognitive decline, and coma. Crucially, yet often disregarded, the disease holds the potential for cure.

Lumbar dural leaks can arise from commonly performed medical interventions such as diagnostic lumbar punctures, spinal anesthesia, spinal infiltrations, or incidental dural punctures during epidural analgesia in obstetric care, resulting in post-dural puncture headache (PDPH).

Additionally, a notable fraction of spinal CSF leaks manifests as spontaneous intracranial hypotension (SIH), which derives from different types of spontaneous leaks along the Spine and remains broadly under-recognized.

The main clinical symptoms of spinal CSF leaks are orthostatic headaches with a most often defined beginning, typically accompanied by hearing impairment and dizziness, worsened by exercise and movement. Additionally, other manifestations are known, such as cognitive decline, bilateral brachial amyotrophy, paradox headache, fatigue, and many more. In patients presenting with spinal CSF leaks, the accurate diagnosis often eludes clinicians, leading to frequent misdiagnoses of chronic migraine, fatigue, or psychiatric conditions. Many patients endure months, if not years, before a diagnosis of a treatable condition is finally established. The heterogeneity of the symptoms can appear inconsistent or even paradoxical, posing diagnostic challenges. The extent of possible long-term deterioration is not recognized.

The reported incidence of PDPH fluctuates considerably, ranging from 2 to 40 per 100 procedures performed. This variance is influenced by patient-related factors (e.g., age, gender, pregnancy status) and procedural factors (e.g., needle size and type). PDPH, according to current criteria, occurs within 5 days after a dural puncture. Nevertheless, there are widely underestimated pitfalls: a dural puncture is not always recognized by the person performing an epidural procedure, symptoms can occur after more than 5 days, and disease courses can be chronic. These facts are widely unknown, leading to largely hidden figures of patients being under or misdiagnosed and, thus, not treated. Moreover, PDPH is primarily observed following unintentional dural puncture during the administration of obstetric anaesthesia and analgesia to parturients.

Spontaneous intracranial hypotension (SIH) can be caused by ventral, lateral, or sacral spinal leaks or by CSF-venous fistulae, which was first described in 2014. An annual incidence rate of \~ 4/100,000 was estimated in 2022. This rate is likely underestimated as it only includes confirmed cases, thus recognized cases within a widely non-recognized entity. Often, patients are neither identified nor directed to the appropriate MRI, which, in numerous instances, could lead to the correct diagnosis. Even when SIH is identified, non-targeted epidural blood patches in the lumbar region are often not administered due to perceived elevated risks. An epidural blood patch might be able to help to heal the leak. At the same time, it must be noted that even long-term improvement does not necessarily indicate closure of the leak and prevention of long-term sequelae, such as superficial siderosis. Invasive diagnostics are not employed to pinpoint the location, and treatment to seal the leak is not consistently pursued. The effects of treatment are often immediate and can be successful even in chronic patients. Evidence shows that leaks are held open by new membranes (Neo-membranes) that prevent spontaneous healing. Thus, the correct localization of such a leak and targeted sealing or close follow-ups should be initiated.

The management approaches for SIH and PDPH significantly deviate from standard pain management strategies employed for other types of headaches. Noteworthy interventions include the application of blood patches and even surgical measures to seal the leak, offering curative solutions. Those enduring chronic spinal CSF leaks experience profound limitations in their health-related quality of life, comparable to those with chronic immunological diseases or cancer. Overlooking the diagnosis and management of spinal CSF leaks may precipitate progressive deterioration, with the potential for persistent sequelae like superficial siderosis, syndromes mimicking frontotemporal dementia (FTD), and chronic subdural hematoma formation.

This registry aims to set ground for standardized, prospective demographic, diagnostic and treatment data assessments, and patient self-reported outcome measures.

Collecting this data is essential to potentially exploring risk factors, understanding outcome predictors, and refining diagnostics. Additionally, standardized data collection will allow the appropriate designing of urgently needed randomized trials.

Aims:

Primary aim:

To describe the proportion of patients diagnosed with SIH or PDPH

Secondary aims:

  1. To describe the proportion of different spinal CSF leaks observed per entity
  2. To describe the demographics per entity, and per different spinal CSF leak type
  3. To describe the clinical spectrum per entity, and per different spinal CSF leak type
  4. To describe the imaging features per entity, and per different spinal CSF leak type
  5. To describe the outcome of different treatments, and per different spinal CSF leak type
  6. To describe the adverse events of different treatments, and per different spinal CSF leak type
  7. To explore potential diagnostic markers per entity, and per different spinal CSF leak type
  8. To explore risk factors per entity, and per different spinal CSF leak type
  9. To evaluate differences between spinal CSF leak types regarding age, sex, BMI, clinical presentation, diagnostic findings
  10. To assess the effect of disease duration on imaging findings, and on outcome after persistent closure of a leak

Method:

The registry is prospective, longitudinal and currently monocentric*. Diagnostic, treatment, and follow-up procedures follow clinical standard operating procedures (SOP) according to the suspected diagnosis and the clinical findings.

Routinely assessed data of the initial diagnostic workup and the individual's disease course with or without treatment will be collected over 2 years per individual. The investigators' semi-annual meetings ensure the achievement of the register's predefined aims.

There are no specific risks or benefits for the patients participating in this registry. Any procedure will be performed according to clinical standards as indicated. There will be no additional visits to the hospital or the ambulatory. There will be no additional imaging performed, especially no additional radiation.

A merely intrinsic benefit might exist for the patient supporting this study and supporting medical research.

As this is an explorative and observational study on rare diseases without formal sample size estimation, we limit the study by time of duration (10 years).

Patients suffering from rare diseases most often face delays in diagnostics and treatments. To underscore this known burden: By an estimated population of 1.74 Mio in the Freiburg area and an incidence rate of SIH of about 5/100.0004, approximately 85 patients should be expected per year stemming from this area. Freiburg is the only center offering adequate diagnostic pipelines for these patients. Despite the increasing awareness, the number of patients diagnosed in the area adjunct to the Freiburg CSF center is within a range of 15 to 20 patients per year, thus still too low compared to the expected number with many patients unrecognized, and or underdiagnosed.

Our current numbers of confirmed SIH treatments range from 100 per year with patients being referred throughout Germany and about 15-20 international patients per year. We expect this rate to rise within the next few years. The number of PDPH patients with a focus on persistent PDPH patients is currently rapidly increasing. We see about 40-60 per year.

Interim-Evaluation of the Registry's primary and secondary descriptive aims will be performed and reported as a step-wise, dynamic approach:

  • After each +100 patients with confirmed SIH
  • After each +50 patients with confirmed PDPH

The secondary objectives, which involve comparisons, the exploration of diagnostic markers, and risk factors, will be addressed using a dynamic biostatistical model: The analysis will only be conducted after a power analysis deems the observed sample adequate.

Proportions will be presented as a percentage with 95% confidence interval (CI).

The sata of patients with different types of spinal CSF leaks will be summarized using descriptive statistics, i.e. median and quartiles for continuous and absolute and relative frequencies for categorical variables, regarding their clinical, laboratory, and diagnostic findings, and number of diagnostic and therapeutic procedures needed.

Furthermore, the proportion of SIH patients with different spinal CSF leak types

  1. will be compared between males and females using a Chi2-Test and a risk difference with 95% CI.
  2. Will be presented by age groups (per two decades), and per sex as a percentage with a 95% Wilson confidence interval (CI).

Age, sex, BMI, clinical presentation, and diagnostic findings between different spinal CSF leaks will be compared using the Mann-Whitney-Wilcoxon test and Chi2 test for continuous and categorical variables, respectively.

A multivariable logistic regression for the presence of SIH, PDPH, and chronic PDPH, respectively, will be constructed using the clinical and diagnostic parameters with some evidence for a difference according to the presence of a spinal CSF leak (p \< 0.2). The potential nonlinearity of the age effect is evaluated based on a residual analysis of the regression model. Odds ratios with 95% CI will be reported. Using bootstrapping, we will present a ROC curve and AUC with 95% Due to the exploratory approach,, no correction for multiple testing will be performed.

A multivariable linear regression for imaging findings (especially Bern Score, presence of SLEC, vand olumetries), and for the patient-reported outcomes will be constructed using the clinical and diagnostic parameters at admission with some evidence for a difference (p\<0.2). Adjusted R-squares, Beta-coefficients with 95% CI, standard errors will be reported.

02

Conditions studied

  • CerebroSpinal Fluid (CSF) Leak

Keywords

  • SIH
  • PDPH
  • Spinal leaks
  • CSF leak
  • SLEC
  • Spontaneouse Intercranial Hypotension
  • CSF-venous fistula
  • Post Dural Puncture Headache
  • Cerebrospinal Fluid Leak
  • Rare disease
03

In context

Post-Dural Puncture Headache

123 studies on the registry are indexed under Post-Dural Puncture Headache; 26 are open to participants now.

This study's planned enrollment of 2,000 is above the median of 150 across 35 observational studies indexed under Post-Dural Puncture Headache.

Browse Post-Dural Puncture Headache studies →

Lead sponsor

University Hospital Freiburg is the lead sponsor of 94 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The registry is an explorative study on patients suffering from a rare disease - therefor it is aimed to include all eligible patients for a time-limit of 10 years. All patients with suspected spinal CSF leak will be approached and informed about the registry. In case of legal incapacity, the caregivers will be approached. The inclusion of this vulnerable group is considerable as they represent a small but very important subgroup of patients suffering from demntia stemming from a traetable cause.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with suspected spinal CSF leak based on one of the following

    • History of new orthostatic symptomes with or without prior spinal procedure
    • Imaging suggestive for spinal CSF leak

Exclusion criteria

Exclusion Criteria:

a) Symptoms beeing conclusively explained by another known diagnosis

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Target follow-up
24 Months
Patient registry
Yes

Groups and cohorts

  • spinal CSF leak

    Patients with suspected spinal CSF leak based on one of the following: 1. History of new orthostatic symptoms with or without prior spinal procedure 2. Imaging suggestive for spinal CSF leak

06

What researchers measure

Primary outcomes

  1. Primary Diagnosis given after primary workup (yes/no)

    * SIH (fulfilling ICHD-3 criteria) - yes/no * atypical SIH - yes/on * Asymptomatic SIH (positive imaging signs only) - yes/no * PDPH (fulfilling ICHD-3-criteria) - yes/no * persistentPDPH - yes/no

    Time frame: up to 4 weeks after inclusion

Secondary outcomes

  1. SIH/PDPH - Experience of the local team

    Number of patient with suspicion for SIH work-up/year

    Time frame: at time of inclusion

  2. SIH/PDPH - Patients' demographics

    Country, City

    Time frame: at time of inclusion

  3. SIH - Previously received treatment at time of inclusion (yes/no)

    Medical SIH treatment, Other symptomatic treatment, Untargeted lumbar blood patch, Targeted blood patch, Targeted fibrin patch, Endovascular embolization, Minimally invasive surgery, Open surgery - dorsal approach, Open surgery-ventral approach, Open surgery-transforaminal approach, Discectomy, Laminectomy, Stabilization procedures, Surgery, other techniques

    Time frame: at time of inclusion

  4. SIH/PDPH - age

    years

    Time frame: at time of inclusion

  5. SIH/PDPH - sex

    male female diverse

    Time frame: at time of inclusion

  6. SIH/PDPH - height

    height in meter (m)

    Time frame: at time of inclusion

  7. SIH/PDPH - weight

    kilogram (kg)

    Time frame: at time of inclusion

  8. SIH/PDPH - modified Ranking scale

    range in 0-6, 0 indicating best health

    Time frame: at time of inclusion

  9. SIH/PDPH - pre-existing Neurological deficits (yes/no)

    Neurological deficits due to previously attempted treatments at the time of inclusion

    Time frame: at time of inclusion

  10. SIH/PDPH - Neurological deficits in routine clinical testing

    descriptive

    Time frame: at time of inclusion

  11. SIH - Montreal cognitive Assessment

    range 0-30, 30 indicating best performance

    Time frame: at time of inclusion

  12. SIH - Trail-making test part B

    in minutes needed to fulfill the task

    Time frame: at time of inclusion

  13. PDPH -BMI

    kg/m\^2

    Time frame: at time of inclusion

  14. SIH/PDPH - Regular use of stimuli > 6 months (yes/no)

    Nicotine, Alcohol, Recreational drugs

    Time frame: at time of inclusion

  15. SIH/PDPH - Headache-Impact-Test (HIT)-6

    Headache-Impact-Test (HIT)-6 range 36 to 78 points, 78 indicating highest impact of headaches.

    Time frame: at time of inclusion

  16. SIH/PDPH - 5 dimensions /5 levels European Quality of life questionaire (EQ-5D-5L) Index

    \<0 to 1, with 1 indicating unimpaired health

    Time frame: at time of inclusion

  17. SIH/PDPH - Self-Administered Comorbidity Questionaire (SCQ)

    13-item Self-Adminestered Comorbidity Questionaire (SCQ), range 0 to 39, 0 indicating lowest burden

    Time frame: at time of inclusion

  18. PDPH - Patient'S Global Impression of Change (PIGC)

    range 7 - 42, 7 indicating highest improvement

    Time frame: at time of inclusion

  19. SIH - Opening pressure on lumbar puncture if performed (not recommended in routine), or myelogram

    cmH2O

    Time frame: up to 4 weeks

  20. SIH/PDPH - Total Bern-Score MRI head according to Dobrocky et al.

    range 0 to 9 with 9 indicating highest likelihood of a spinal CSF leak

    Time frame: up to 4 weeks

  21. SIH/PDPH - Subitems Bern-Score MRI head according to Dobrocky et al.

    Meningeal enhancement (yes/no), Subdural fluid (yes/no), Venous Distention (yes/no), Effaced suprasellar distance (yes/no), Effaced mamillopontine distance (yes/no), Effaced prepontine distance (yes/no)

    Time frame: up to 4 weeks

  22. SIH - MRI head - Superficial Siderosis

    (yes/no)

    Time frame: up to 4 weeks

  23. SIH - MRI head - Layered calvarial hyperostosis

    (yes/no)

    Time frame: up to 4 weeks

  24. SIH - Sinus vein thrombosis

    (yes/no)

    Time frame: up to 4 weeks

  25. SIH/PDPH - Volumetry of the CSF-space MRI head & spine

    mm\^3

    Time frame: up to 4 weeks

  26. SIH/PDPH - Volumetry of the CNS MRI head & spine

    mm\^3

    Time frame: up to 4 weeks

  27. SIH/PDPH - Imaging Density score

    Density scores of the intracranial compartments MRI head \& spine

    Time frame: up to 4 weeks

  28. SIH/PDPH - Total radiation dose applied per diagnostic procedure with radiation performed

    Sievert

    Time frame: at primary workup

  29. SIH - Myelography number

    Number of myelographies performed for precise localization

    Time frame: up to 24 weeks

  30. SIH - Type of myelography technique applied (yes/no)

    conventional,digital subtraction, dynamic CT, Cone-beam CT, Photon-counting CT, fluoroscopy, Other (specify)

    Time frame: up to 4 weeks

  31. SIH - Adverse events during myelography (yes/no)

    nausea, dizziness/vertigo, emesis, allergic reaction, seizure, treatment intensive care unit (independent of cause))

    Time frame: up to 4 weeks

  32. SIH - Headache before and after myelogram

    in 0-10, 10 numeric rating scale

    Time frame: up to 4 weeks

  33. SIH - Positioning during index myelography that proofs the leak (yes/no)

    prone, lateral decubitus, supine

    Time frame: up to 4 weeks

  34. SIH - myelography that proofs the leak performed applying (yes/no)

    resisted insipration, pressuization, valsalva maneuver

    Time frame: up to 4 weeks

  35. SIH/PDPH - Lumbar Infusiontest - Pressure at baseline

    pressure (mmHg)

    Time frame: up to 4 weeks

  36. SIH/PDPH - Lumbar Infusiontest - Resistence to CSF outflow (Rcsf)

    mmHg/(ml/min)

    Time frame: up to 4 Weeks

  37. SIH/PDPH - Lumbar Infusiontest - Elastance

    Elastance coefficient (1/ml)

    Time frame: up to 4 weeks

  38. SIH/PDPH - Lumbar Infusiontest - Pressure-Volume-Index

    ml

    Time frame: up to 4 weeks

  39. SIH/PDPH - Lumbar Infusiontest - Needle resistance

    Time frame: up to 4 weeks

  40. SIH/PDPH - PET-CT - Evidence of CSF-loss (yes/no)

    Time frame: up to 4 weeks

  41. SIH/PDPH - PET-CT if performed -

    half-life of the tracer in the CSF space (minutes)

    Time frame: up tp 4 weeks

  42. SIH/PDPH - Laboratory parameters at diagnosis (normal/abnormal)

    * complete routine Blood analysis (including: cellcount, electrolytes, coagulation, renal function, thyroid marker) (normal/abnormal) * complete routine CSF-analysis (including: cell count, protein) (normal/abnormal)

    Time frame: up to 4 weeks after inclusion

  43. SIH - CSF leak types identified by dynamic myelography (yes/no)

    * Ventral dural leak * Lateral dural leak * CSF-venous fistula, single * CSF-venous fistula, multiple * Sacral dural leak * CSF-lymphatic fistula * Dorsal dural leak * Undefined

    Time frame: up to 4 weeks

  44. SIH - Multiples leaks (yes/no)

    Time frame: up to 4 weeks

  45. SIH - Level of spinal CSF leak (spinal segment) and side in myelogram

    Time frame: up to 4 weeks

  46. SIH - In case of surgery: spinal segment and side confirmed? (yes/no)

    Time frame: up to 4 weeks

  47. SIH/PDPH - Experience of leading interventionalist in SIH-diagnostics/year

    Time frame: up to 4 weeks

  48. SIH/PDPH - Disease duration at time of therapy

    month

    Time frame: up to 4 weeks

  49. SIH/PDPH - Therapy performed after CSF leak diagnosis (yes/no)

    Untargeted lumbar blood patch, Targeted blood patch, Targeted fibrin patch, Endovascular embolization, Minimally invasive surgery with patching, Minimally invasive surgery with clipping, Minimally invasive surgery with disconnection, Open surgery, dorsal approach, Open surgery, ventral approach, Open surgery, transforaminal approach, Surgery, other techniques, Medical PDPH treatment, Other symptomatic treatment, e.g. infiltration N. occipitalis, Untargeted lumbar platelet-rich fibrin patch

    Time frame: up to 4 weeks

  50. SIH/PDPH - Experience of leading surgeon in SIH/PDPH-surgeries/year

    in numbers of SIH/PDPH-surgeries/year

    Time frame: up to 4 weeks or longer, depending on the number of surgeries

  51. SIH/PDPH - Interventions needed addressing secondary complications of spinal CSF leaks, especially chronic subdural hematoma

    Twist drill craniostomy (yes/no), Burr hole craniostomy (yes/no ), Mini craniotomy (yes/no), Conventional trepanation (yes/no), Use of drains and any form of controlled lavage (saline and or clot lysis) (yes/no,), Embolization of MMA (middle meningeal arteria) (yes/no), Other intervention (yes/no)

    Time frame: up to 4 weeks

  52. PDPH - Event of putative dural puncture

    date

    Time frame: up to 4 weeks

  53. PDPH - Event of putative dural puncture (yes/ no)

    * Diagnostic lumbar puncture * Diagnostic lumbar puncture with drainage in idiopathic intracranial hypertension * Diagnostic lumbar puncture with drainage in idiopathic normal-pressure hydrocephalus * Peridural anesthesia in obstetrics * Spinal anesthesia in obstetrics * Peridural anesthesia, other intervention * Spinal anesthesia, other intervention * Infiltration * others

    Time frame: up to 4 weeks

  54. SIH/PDPH - adverse events related to current treatment at discharge (yes/no)

    Rebound hypertension, Persistence/Reoccurrence of the leak, Suture insufficiency, Infect (systemic/local), Bleeding, Sensory deficits, Motor deficits, Gait ataxia, Bladder dysfunction, Bowl dysfunction, Others

    Time frame: up to 4 weeks

  55. PDPH - Lumbar segment of putative dural puncture known (yes/no)

    Time frame: up to 4 weeks

  56. PDPH - Puncture under imaging guidance

    "location truly known"

    Time frame: up to 4 weeks

  57. PDPH - Duration between (putative) dural puncture until the onset of symptoms

    days

    Time frame: up to 4 weeks

  58. PDPH - Time to first blood patch

    days

    Time frame: up to 4 weeks

  59. PDPH - Number of bloodpatches received before admission

    Time frame: up to 4 weeks

  60. PDPH - Prior treatments at the time of admission (yes/no)

    Fluids, Caffeine, Bedrest, Medical treatment, Other treatment, e.g., infiltrations, Untargeted lumbar bloodpatch, Surgery

    Time frame: up to 4 weeks

  61. PDPH - Post-dural puncture pseudomeningocele ("arachnoid bleb")

    (yes/no)

    Time frame: up to 4 weeks

  62. PDPH - Spinal Segment location of the "arachnoid bleb"

    Time frame: up to 4 weeks

  63. PDPH - Identified CSF leak types by dynamics myelography and/or intraoperatively:

    ventral post-dural puncture leak, dorsal post-dural puncture pseudomeningocele ("arachnoid bleb"), dorsal post-dural puncture leak None

    Time frame: up to 4 weeks

  64. PDPH - Intraoperatively Identified membranes (yes/no)

    neo-membranes (pseudo dura), webs, funnels

    Time frame: up to 4 weeks

  65. PDPH - Dinosaur-tail sign (yes/no)

    Time frame: at time of inclusion

  66. PDPH - specific segment of identified intraoperative membranes (descriptive)

    Time frame: up to 4 weeks

  67. PDPH - CSF leak types identified by dynamic myelography and/or intraoperatively

    ventral post-dural puncture leak, dorsal post-dural puncture pseudomeningocele ("arachnoid bleb"), dorsal post-dural puncture leak, None

    Time frame: up to 4 weeks

  68. PDPH - Diagnostic procedures performed (yes/no, number)

    CT Head, MRI head, MRI spine, Dynamic digital subtraction myelogram, Dynamic CT-myelogram, Photon-counting CT-myelogram, Cone-beam myelogram, Infusion testing, PET-CT, Other (to exclude/confirm alternative diagnosis)

    Time frame: uo to 4 weeks

  69. PDPH - Volume lumbar bloodpatch

    ml

    Time frame: up to 4 weeks

  70. SIH/PDPH - work capacity

    range 0 to 5, 0 indicating full capacity

    Time frame: at time of inclusion

  71. SIH/PDPH -complaints

    * current complaints (descriptively) * most stressful complaint (descriptively)

    Time frame: at time of inclusion

  72. SIH/PDPH - headache severity

    range 0 to 10, 10 indicating most severe pain

    Time frame: at time of inclusion

  73. SIH/PDPH - Days within the last month

    * with headaches * with pain medication intake in the last month

    Time frame: at time of inclusion

  74. SIH/PDPH - maximum duration being continuously upright

    hours

    Time frame: at time of inclusion

  75. SIH/PDPH - severeness of dizziness

    - in 0 to 10, 10 being most severe

    Time frame: at time of inclusion

  76. SIH/PDPH - Severeness of shoulder- and neck pain

    - in 0 to 10, 10 being most severe

    Time frame: at time of inclusion

  77. SIH/PDPH - severeness of nausea

    - in 0 to 10, 10 being most severe

    Time frame: at time of inclusion

  78. SIH/PDPH - severeness of hearing disturbances and tinnitus

    - in 0 to 10, 10 being most severe

    Time frame: at time of inclusion

  79. SIH/PDPH - severeness of cognitive deficits

    - in 0 to 10, 10 being most severe

    Time frame: at time of inclusion

  80. SIH/PDPH - severeness of visual disturbances

    - in 0 to 10, 10 being most severe

    Time frame: at time of inclusion

  81. SIH/PDPH - . ability to focus and concentrate

    rated between 0 to 5, with 5 indicating highest burden

    Time frame: at time of inclusion

  82. SIH/PDPH - MRI spine: Spinal longitudinal extradural fluid collection (SLEC) (yes/no)

    Time frame: up to 4 weeks

  83. SIH/PDPH - MRI-spine: DiverTICula (TIC) ≥8mm (yes/no)

    number of TICs ≥8mm

    Time frame: up to 4 weeks

  84. SIH/PDPH - Volumetry of epidural spinal veins at C2

    mm\^3

    Time frame: up to 4 weeks

  85. SIH/PDPH - MRI spine: Enlarged cervical epidural spinal veins at C2

    yes/no

    Time frame: up to 4 weeks

  86. SIH/PDPH - lumbar infusion test - pressure at tilt down

    mmHg

    Time frame: up to 4 weeks after inclusion

  87. SIH/PDPH - lumbar infusion test - pressure at tilt up 10°

    mmHg

    Time frame: up to 4 weeks after inclusion

  88. SIH/PDPH - lumbar infusion test - pressure at tilt up 30°

    mmHg

    Time frame: up to 4 weeks after inclusion

  89. SIH/PDPH - lumbar infusion test - pressure at plateau

    mmHg

    Time frame: up to 4 weeks after inclusion

  90. SIH/PDPH - Laboratory parameters at diagnosis (decriptive)

    * Routine Blood analysis * Abnormal CSF-analysis

    Time frame: up to 4 weeks after inclusion

  91. SIH/PDPH - Lumbar Infusiontest - amplitude at baseline

    mmHg

    Time frame: up to 4 weeks

  92. SIH/PDPH - lumbar infusion test - amplitude at tilt down

    mmHg

    Time frame: up to 4 weeks after inclusion

  93. SIH/PDPH - lumbar infusion test -amplitude at tilt up 10°

    mmHg

    Time frame: up to 4 weeks after inclusion

  94. SIH/PDPH - lumbar infusion test - amplitude at tilt up 30°

    mmHg

    Time frame: up to 4 weeks after inclusion

  95. SIH/PDPH - lumbar infusion test - amplitude at plateau

    mmHg

    Time frame: up to 4 weeks after inclusion

  96. SIH/PDPH - PET-CT if performed -

    half-life of the tracer o0ver the convexities (minutes)

    Time frame: up tp 4 weeks

  97. SIH/PDPH - Results of neuropathological tissue analysis if assessed (descriptive)

    epidural membranes (descriptive) arachnoid funnels (descriptive) diverticula (descriptive) epidural vessels (descriptive)

    Time frame: up to 6 weeks

  98. SIH/PDPH - phase-contrast MRI : CSF-velocity

    cm/s

    Time frame: up to 4 weeks

  99. SIH/PDPH - phase-contrast MRI: Stroke-volume CSF

    ml

    Time frame: up to 4 weeks

  100. SIH/PDPH - phase-contrast MRI: Spinal cord motion

    mm

    Time frame: up to 4 weeks

  101. SIH/PDPH - phase-contrast MRI: Spinal cord velocities

    cm/s

    Time frame: up to 4 weeks

  102. SIH/PDPH - MRI spine: Bud-on-branching sign (yes/no)

    Time frame: up to 4 weeks

  103. SIH/PDPH - MRI spine: Localized flow-voids in sagittal spine T2 images (yes/no)

    Time frame: up to 4 weeks

Other outcomes

  1. SIH/PDPH - Follow up-Reported adverse events related to treatment (yes/no)

    Rebound hypertension, Reoccurrence of the leak, Suture insufficiency, Bleeding, Sensory deficits, Motor deficits, Gait ataxia, Bladder dysfunction, Bowl dysfunction, Others

    Time frame: 4 weeks and 3 month after treatment

  2. SIH/PDPH - Follow up-Duration of treatment for rebound hypertension after therapy of the CSF leak

    days

    Time frame: 4 weeks after treatment

  3. SIH/PDPH - Follow up-Average dosage of acetazolamide per day

    mean mg/d

    Time frame: 4 weeks after treatment

  4. SIH/PDPH - Follow up - Total Bern-Score, according to Dobrocky et al.

    range 0 to 9, 9 indicating highest likelihood of spinal CSF leak

    Time frame: 3 months after treatment

  5. SIH/PDPH - Follow up - Subitems Bern-Score, according to Dobrocky et al.

    * Meningeal enhancement (yes/no) * Subdural fluid (yes/no) * Venous distention (yes/no) * Effaced suprasellar distance (yes/no) * Effaced mamillopontine distance (yes/no) * Effaced prepontine distance (yes/no)

    Time frame: 3 months after treatment

  6. SIH/PDPH - Follow up - Spinal longitudinal extradural fluid collection at site of the leak (SLEC) (only if present before)

    yes /no

    Time frame: 3 months after treatment

  7. SIH/PDPH - Follow up - Headache-Impact-Test (HIT)-6

    range 36 to 78 points, 78 indicating highest impact of headaches

    Time frame: 3, 6, 12 & 24 months after treatment

  8. SIH/PDPH - Follow up - 5 dimension/ 5 levels European Quality of life questionnaire (EQ-5D-5L)

    \<0 to1, 1indicating unimpaired health

    Time frame: 3, 6, 12, & 24 months after treatment

  9. SIH/PDPH - Follow up - Patient's Global Impression of Change (PGIC)

    range 7 to 42, 7 indicating highest improvement

    Time frame: 3, 6, 12 & 24 months after treatment

  10. SIH/ PDPH - Follow up - Self-administered comorbidity questionnaire (SCQ)

    range 0 to 39, 0 indicating lowest burden

    Time frame: 12 & 24 months after treatment

  11. SIH/PDPH - follow-up - current working capacity

    range 0 to 5, 0 indicating full capacity

    Time frame: at 4 weeks & 3, 6, 12 & 24 months

  12. SIH/PDPH - follow-up - complaints

    * current complaints (descriptively) * most stressful complaint (descriptively)

    Time frame: 4 week, 3, 6, 12 & 24 months

  13. SIH/PDPH - follow-up - headache severity

    range 0 to 10, 10 indicating most severe pain

    Time frame: 4 week, 3, 6, 12 & 24 months

  14. SIH/PDPH - follow-up - Days within the last month

    with headaches with pain medication intake in the last month

    Time frame: 4 weeks, 3, 6, 12, 24 months

  15. SIH/PDPH - follow-up - maximum duration being continuously upright

    hours

    Time frame: 4 weeks, 3, 6, 12 & 24 months

  16. SIH/PDPH - follow-up - severeness of dizziness

    - in 0 to 10, 10 being most severe

    Time frame: 4 weeks, 3, 6, 12 &24 months

  17. SIH/PDPH - follow-up - Severeness of shoulder- and neck pain

    in 0 to 10, 10 being most severe

    Time frame: 4 weeks, 3, 6, 12 & 24 months

  18. SIH/PDPH - follow-up - severeness of nausea

    in 0 to 10, 10 being most severe

    Time frame: 4 weeks, 3, 6, 12 & 24 months

  19. SIH/PDPH - follow-up - severeness of hearing disturbances and tinnitus

    in 0 to 10, 10 being most severe

    Time frame: 4 weeks, 3, 6, 12 & 24 months

  20. SIH/PDPH - follow-up - severeness of cognitive deficits

    in 0 to 10, 10 being most severe

    Time frame: 4 weeks, 3, 6, 12 & 24 months

  21. SIH/PDPH - follow-up - severeness of visual disturbances

    in 0 to 10, 10 being most severe

    Time frame: 4 weeks, 3, 6, 12 & 24 months

  22. SIH/PDPH - follow-up - exhaustion

    rated between 0 to 5, with 5 indicating highest burden

    Time frame: 4 weeks, 3, 6,12 &24 months

  23. SIH/PDPH - follow-up - ability to focus and concentrate

    rated between 0 to 5, with 5 indicating highest burden

    Time frame: 4 weeks, 3, 6, 12 & 24 months

  24. SIH/PDPH - follow-up - phase-contrast MRI: CSF-velocity (if performed)

    cm/s

    Time frame: up to 6 months after treatment

  25. SIH/PDPH - follow-up - phase-contrast MRI Stroke-volume CSF (if performed)

    ml

    Time frame: up to 6 months after treatment

  26. SIH/PDPH - follow-up - phase-contrast MRI Spinal cord motion (if performed)

    mm

    Time frame: up to 6 months after treatment

  27. SIH/PDPH - follow-up - phase-contrast MRI Spinal cord velocity (if performed)

    cm/s

    Time frame: up to 6 months after treatment

07

Study locations

1 of 1 sites recruiting
  • Medical Center - University of Freiburg, Germany
    Freiburg, 79106, Germany
    Recruiting
08

References and documents

Publications

  • Schievink WI, Maya MM, Moser FG, Simon P, Nuno M. Incidence of spontaneous intracranial hypotension in a community: Beverly Hills, California, 2006-2020. Cephalalgia. 2022 Apr;42(4-5):312-316. doi: 10.1177/03331024211048510. Epub 2021 Sep 23. PubMed 34553617 ↗
  • Lashkarivand A, Eide PK. Brain Sagging Dementia-Diagnosis, Treatment, and Outcome: A Review. Neurology. 2022 May 10;98(19):798-805. doi: 10.1212/WNL.0000000000200511. Epub 2022 Mar 25. PubMed 35338080 ↗
  • Schievink WI, Maya M, Barnard Z, Tache RB, Prasad RS, Wadhwa VS, Moser FG, Nuno M. The reversible impairment of behavioral variant frontotemporal brain sagging syndrome: Challenges and opportunities. Alzheimers Dement (N Y). 2022 Dec 18;8(1):e12367. doi: 10.1002/trc2.12367. eCollection 2022. PubMed 36544987 ↗
  • Schievink WI, Maya MM, Harris J, Galvan J, Tache RB, Nuno M. Infratentorial Superficial Siderosis and Spontaneous Intracranial Hypotension. Ann Neurol. 2023 Jan;93(1):64-75. doi: 10.1002/ana.26521. Epub 2022 Oct 22. PubMed 36200700 ↗
  • Sprave T, Gkika E, Verma V, Grosu AL, Stoian R. Patient reported outcomes based on EQ-5D-5L questionnaires in head and neck cancer patients: a real-world study. BMC Cancer. 2022 Nov 29;22(1):1236. doi: 10.1186/s12885-022-10346-4. PubMed 36447175 ↗
  • Cella D, Grunwald V, Escudier B, Hammers HJ, George S, Nathan P, Grimm MO, Rini BI, Doan J, Ivanescu C, Paty J, Mekan S, Motzer RJ. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncol. 2019 Feb;20(2):297-310. doi: 10.1016/S1470-2045(18)30778-2. Epub 2019 Jan 15. Erratum In: Lancet Oncol. 2019 Jun;20(6):e293. doi: 10.1016/S1470-2045(19)30348-1. PubMed 30658932 ↗
  • Niraj G, Mushambi M, Gauthama P, Patil A, Kelkar A, Hart E, Nurmikko T; Accidental Dural Puncture Outcome Study Collaborative Group. Persistent headache and low back pain after accidental dural puncture in the obstetric population: a prospective, observational, multicentre cohort study. Anaesthesia. 2021 Aug;76(8):1068-1076. doi: 10.1111/anae.15491. Epub 2021 Apr 23. PubMed 33891312 ↗
  • Ranganathan P, Golfeiz C, Phelps AL, Singh S, Shnol H, Paul N, Attaallah AF, Vallejo MC. Chronic headache and backache are long-term sequelae of unintentional dural puncture in the obstetric population. J Clin Anesth. 2015 May;27(3):201-6. doi: 10.1016/j.jclinane.2014.07.008. Epub 2014 Dec 4. PubMed 25483233 ↗
  • MacArthur C, Lewis M, Knox EG. Accidental dural puncture in obstetric patients and long term symptoms. BMJ. 1993 Apr 3;306(6882):883-5. doi: 10.1136/bmj.306.6882.883. PubMed 8490410 ↗
  • Piechowiak EI, Aeschimann B, Hani L, Kaesmacher J, Mordasini P, Jesse CM, Schankin CJ, Raabe A, Schar RT, Gralla J, Beck J, Dobrocky T. Epidural Blood Patching in Spontaneous Intracranial Hypotension-Do we Really Seal the Leak? Clin Neuroradiol. 2023 Mar;33(1):211-218. doi: 10.1007/s00062-022-01205-7. Epub 2022 Aug 26. PubMed 36028627 ↗
  • Beck J, Hubbe U, Klingler JH, Roelz R, Kraus LM, Volz F, Lutzen N, Urbach H, Kieselbach K, Fung C. Minimally invasive surgery for spinal cerebrospinal fluid leaks in spontaneous intracranial hypotension. J Neurosurg Spine. 2022 Sep 9;38(1):147-152. doi: 10.3171/2022.7.SPINE2252. Print 2023 Jan 1. PubMed 36087332 ↗
  • Carlton Jones L, Butteriss D, Scoffings D. Spontaneous intracranial hypotension: the role of radiology in diagnosis and management. Clin Radiol. 2022 Mar;77(3):e181-e194. doi: 10.1016/j.crad.2021.11.007. Epub 2021 Dec 20. PubMed 34949452 ↗
  • Dobrocky T, Grunder L, Breiding PS, Branca M, Limacher A, Mosimann PJ, Mordasini P, Zibold F, Haeni L, Jesse CM, Fung C, Raabe A, Ulrich CT, Gralla J, Beck J, Piechowiak EI. Assessing Spinal Cerebrospinal Fluid Leaks in Spontaneous Intracranial Hypotension With a Scoring System Based on Brain Magnetic Resonance Imaging Findings. JAMA Neurol. 2019 May 1;76(5):580-587. doi: 10.1001/jamaneurol.2018.4921. PubMed 30776059 ↗
  • Pradeep A, Madhavan AA, Brinjikji W, Cutsforth-Gregory JK. Incidence of spontaneous intracranial hypotension in Olmsted County, Minnesota: 2019-2021. Interv Neuroradiol. 2023 Mar 22:15910199231165429. doi: 10.1177/15910199231165429. Online ahead of print. PubMed 36945844 ↗
  • Farb RI, Nicholson PJ, Peng PW, Massicotte EM, Lay C, Krings T, terBrugge KG. Spontaneous Intracranial Hypotension: A Systematic Imaging Approach for CSF Leak Localization and Management Based on MRI and Digital Subtraction Myelography. AJNR Am J Neuroradiol. 2019 Apr;40(4):745-753. doi: 10.3174/ajnr.A6016. Epub 2019 Mar 28. PubMed 30923083 ↗
  • Hani L, Fung C, El Rahal A, Volz F, Kraus LM, Schnell O, Ferrarese R, Erny D, Schwabenland M, Urbach H, Lutzen N, Beck J. Distinct Pattern of Membrane Formation With Spinal Cerebrospinal Fluid Leaks in Spontaneous Intracranial Hypotension. Oper Neurosurg (Hagerstown). 2024 Jan 1;26(1):71-77. doi: 10.1227/ons.0000000000000914. Epub 2023 Sep 25. PubMed 37747369 ↗
  • Uppal V, Russell R, Sondekoppam RV, Ansari J, Baber Z, Chen Y, DelPizzo K, Dirzu DS, Kalagara H, Kissoon NR, Kranz PG, Leffert L, Lim G, Lobo C, Lucas DN, Moka E, Rodriguez SE, Sehmbi H, Vallejo MC, Volk T, Narouze S. Evidence-based clinical practice guidelines on postdural puncture headache: a consensus report from a multisociety international working group. Reg Anesth Pain Med. 2024 Jul 8;49(7):471-501. doi: 10.1136/rapm-2023-104817. PubMed 37582578 ↗
  • Jesse CM, Hani L, Fung C, Ulrich CT, Schar RT, Dobrocky T, Piechowiak EI, Goldberg J, Schankin C, Sintonen H, Beck J, Raabe A. The impact of spontaneous intracranial hypotension on social life and health-related quality of life. J Neurol. 2022 Oct;269(10):5466-5473. doi: 10.1007/s00415-022-11207-7. Epub 2022 Jun 14. PubMed 35701531 ↗
  • Beck J, Ulrich CT, Fung C, Fichtner J, Seidel K, Fiechter M, Hsieh K, Murek M, Bervini D, Meier N, Mono ML, Mordasini P, Hewer E, Z'Graggen WJ, Gralla J, Raabe A. Diskogenic microspurs as a major cause of intractable spontaneous intracranial hypotension. Neurology. 2016 Sep 20;87(12):1220-6. doi: 10.1212/WNL.0000000000003122. Epub 2016 Aug 26. PubMed 27566748 ↗
  • Kilic K, Korsbaek JJ, Jensen RH, Cvetkovic VV. Diagnosis of idiopathic intracranial hypertension - the importance of excluding secondary causes: A systematic review. Cephalalgia. 2022 May;42(6):524-541. doi: 10.1177/03331024211056580. Epub 2021 Nov 25. PubMed 34822742 ↗
  • Ducros A, Biousse V. Headache arising from idiopathic changes in CSF pressure. Lancet Neurol. 2015 Jun;14(6):655-68. doi: 10.1016/S1474-4422(15)00015-0. PubMed 25987284 ↗
  • Cheema S, Anderson J, Duncan C, Davagnanam I, Armstrong P, Redfern N, Ordman A, D'Antona L, Nissen J, Sayal P, Vaughan-Huxley E, Lagrata S, Iodice V, Snape-Burns J, Joy C, Matharu M. Survey of healthcare professionals' knowledge, attitudes and practices regarding spontaneous intracranial hypotension. BMJ Neurol Open. 2022 Sep 5;4(2):e000347. doi: 10.1136/bmjno-2022-000347. eCollection 2022. PubMed 36110926 ↗
  • Cheema S, Joy C, Pople J, Snape-Burns J, Trevarthen T, Matharu M. Patient experience of diagnosis and management of spontaneous intracranial hypotension: a cross-sectional online survey. BMJ Open. 2022 Jan 20;12(1):e057438. doi: 10.1136/bmjopen-2021-057438. PubMed 35058269 ↗
  • Hani L, Fung C, Jesse CM, Ulrich CT, Piechowiak EI, Gralla J, Raabe A, Dobrocky T, Beck J. Outcome after surgical treatment of cerebrospinal fluid leaks in spontaneous intracranial hypotension-a matter of time. J Neurol. 2022 Mar;269(3):1439-1446. doi: 10.1007/s00415-021-10710-7. Epub 2021 Jul 18. PubMed 34274993 ↗
  • Volz F, Fung C, Wolf K, Lutzen N, Urbach H, Kraus LM, Omer M, Beck J, El Rahal A. Recovery and long-term outcome after neurosurgical closure of spinal CSF leaks in patients with spontaneous intracranial hypotension. Cephalalgia. 2023 Aug;43(8):3331024231196808. doi: 10.1177/03331024231195830. PubMed 37652456 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Dec 2034, 121 months after the start.

Of 18 observational studies under Post-Dural Puncture Headache, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 38. This study's planned 121 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2024
First posted
Dec 2, 2024
StartActual
Nov 4, 2024
Primary completionEst.
Dec 4, 2034
CompletionEst.
Dec 4, 2036
Last update
Dec 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06711731
Lead sponsor
University Hospital Freiburg
Responsible party
Myriam Peters (Scientist, University Hospital Freiburg) — Principal investigator
First posted
Dec 2, 2024
Start date
Nov 4, 2024
Primary completion
Dec 4, 2034 (estimated)
Completion
Dec 4, 2036 (estimated)
Last update
Dec 2, 2024

Study contacts

Katharina Wolf, Dr. med.
Contact
katharina.wolf@uniklinik-freiburg.de
+49 761 270-50010
Florian Volz, Dr. med.
Contact
florian.volz@uniklinik-freiburg.de

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion